Tamoxifen for early breast cancer: an overview of the randomised trials

1988, Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women, N Engl J Med, 319, 1681, 10.1056/NEJM198812293192601 1990 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women, Lancet, 339, 1 1995, Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials, N Engl J Med, 333, 1444, 10.1056/NEJM199511303332202 1996, Ovarian ablation in early breast cancer: overview of the randomised trials, Lancet, 348, 1189, 10.1016/S0140-6736(96)05023-4 Knight, 1980, Hormonal receptors in primary and advanced breast cancer, Clin Endocrinol Metab, 9, 361, 10.1016/S0300-595X(80)80038-7 Elwood, 1980, Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients, Br J Cancer, 42, 635, 10.1038/bjc.1980.296 1992, vol VI Rutqvist, 1995, Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies, J Natl Cancer Inst, 87, 645, 10.1093/jnci/87.9.645 1996, IARC monograph on the evaluation of carcinogenic risks to humans, Some pharmaceutical drugs, 66, 253 Rutqvist, 1989, Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials, Int J Radiation Oncol Biol Phys, 16, 629, 10.1016/0360-3016(89)90478-1 McDonald, 1995, Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial, BMJ, 311, 977, 10.1136/bmj.311.7011.977 Fisher, 1994, Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J Natl Cancer Inst, 86, 527, 10.1093/jnci/86.7.527 Williams, 1993, The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat, Carcinogenesis, 14, 315, 10.1093/carcin/14.2.315 Peto, 1994 Clark, 1997, Estrogen receptor status determined by immuno-histochemistry is superior to biochemical ligand-binding assay for evaluating breast cancer patients, Proc ASCO, 16, 454 1996, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer, J Natl Cancer Inst, 88, 1543, 10.1093/jnci/88.21.1543 1996, Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer, J Natl Cancer Inst, 88, 1834, 10.1093/jnci/88.24.1834 Delozier, 1997, Short-term versus lifelong adjuvant tamoxifen in early breast cancer (EBC): a randomized trial (TAM-01), Proc ASCO, 16, 1289 Peto, 1996, Five years of tamoxifen—or more?, J Natl Cancer Inst, 88, 1791, 10.1093/jnci/88.24.1791 Fisher, 1996, The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors, J Natl Cancer Inst, 88, 1529, 10.1093/jnci/88.21.1529 Stewart, 1996, Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group, Br J Cancer, 74, 297, 10.1038/bjc.1996.356 Tormey, 1996, (for the Eastern Cooperative Oncology Group). Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer, J Natl Cancer Inst, 88, 1828, 10.1093/jnci/88.24.1828 Cuzick, 1996, Chemoprevention of breast cancer with tamoxifen, 95 Love, 1991, Effects of tamoxifen on cardiovascular risk factors in postmenopausal women, Ann Intern Med, 115, 860, 10.7326/0003-4819-115-11-860 Gotto, 1997, Results of recent large cholesterol-lowering trials and implications for clinical management, Am J Cardiol, 79, 1663, 10.1016/S0002-9149(97)00218-X